Evaluation of the Diagnostic Performance of Dynamic Myocardial Perfusion Scintigraphy in Comparison With Invasive Intracoronary FFR Measurement, in the Assessment of Significant Residual Coronary Stenosis After Acute Coronary Syndrome: Dyna-MI Pilot Study.

Nantes University Hospital (NUH)

Status: Enrolling

Conditions: Myocardial Infarction

Treatments: Diagnostic Test: Dynamic 99mTc-Tetrofosmin CZT-SPECT

Study type: Interventional

Funder types: Other

Identifiers

NCT05940285

RC22_0698

Details and patient eligibility

About

Dynamic 99mTc-Tetrofosmin CZT-SPECT myocardial perfusion imaging (MPI) is an advanced functional imaging technique giving important myocardial flow quantification added data in comparison with conventional MPI, especially in coronary multi vessel disease. A large-scale validation of diagnostic performances of myocardial flow reserve (MFR) estimated with Dynamic 99mTc-Tetrofosmin CZT-SPECT MPI would allow a non-invasive approach instead of invasive intra-coronary fractional flow reserve (FFR) measurement. The aim of this prospective study is to assess diagnostic performances of MFR calculated with dynamic 99mTc-Tetrofosmin CZT-SPECT MPI in comparison with invasive intra-coronary FFR measurement in patients with significant residual coronary arteries stenosis after acute coronary syndrome .

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient.

• Multi vessel coronary arteries disease (at least one non-culprit coronary stenosis >= 50%) diagnosis during

  • primary percutaneous coronary intervention < 12h after ST-elevation myocardial infarction opercutaneous revascularisation of the culprit lesion within 24 to 48 hours of an acute non-ST-segment elevation coronary syndrome.

• Written consent.

• Social security affiliation

Exclusion criteria

• Non adult patient.
• Adult patient under tutelage.
• Reproductive age women.
• Medical history of myocardial infarction or coronary artery bypass surgery.
• Cardiogenic shock.
• Cardiomyopathy.
• Regadenoson/adenosine/FFR contraindication.
• 99mTc-Tetrofosmin hypersensibility.
• Small non-culprit coronary arteries.
• Participation to another interventional study.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

60 participants in 1 patient group

Single arm study

Experimental group

Description:

Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment

Treatment:

Diagnostic Test: Dynamic 99mTc-Tetrofosmin CZT-SPECT